FOLH1 and neoplasm: Dosimetric modelling for [177Lu]Lu-PSMA-based RLT showed that the maximum absorbed radiation dose per tumour per treatment cycle was a median 5-fold higher (IQR: 2–24) after ssIA administration (68 Gy, IQR: 33–110) compared to IV administration (10 Gy, IQR: 6–26), and therefore well beyond the estimated 95% CI after IV administration (86.8, 95% CI: 46.8–133.9 versus 14.7, 95% CI: 8.3–21.9).